Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Roche’s Genentech has notched another success on its way to challenging Regeneron — as well as the other Big Pharma contender Novartis — for the blockbuster crown now worn by Eylea.
Researchers at the big sub say that their bispecific Ang-2/VEGF drug faricimab (you once knew it as RG7716) came up with an improved profile over their franchise player Lucentis as a long-acting drug for wet AMD. And they scored on long acting 16-week data, while Regeneron $REGN and Novartis $NVS have been duking it out over the 12-week niche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.